NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
The article deals with the new oral target drug Palbociclib and its place in estrogen-receptor therapy, a positive HER2-negative metastatic breast cancer. Until recently, the consistent endocrine therapy was the primary treatment for the patients of this subgroup, as it significantly improved clinic...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-06-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1884 |
| _version_ | 1797842070435528704 |
|---|---|
| author | E. V. ARTAMONOVA |
| author_facet | E. V. ARTAMONOVA |
| author_sort | E. V. ARTAMONOVA |
| collection | DOAJ |
| description | The article deals with the new oral target drug Palbociclib and its place in estrogen-receptor therapy, a positive HER2-negative metastatic breast cancer. Until recently, the consistent endocrine therapy was the primary treatment for the patients of this subgroup, as it significantly improved clinical outcomes of the disease. However, in the vast majority of cases, the tumor demonstrated the acquired, and sometimes the original, hormone resistance, which sooner or later led to failure of treatment and to the progress of the disease. Discovery of the role of cycline- dependent kinases (CDK) in the activation of the tumor proliferation and the subsequent creation of the first inhibitor, CDK 4 and 6 types of Palbociclib, led to a fundamental change in the situation: The results of the clinical examination of the combinations of Palbociclib with Letrozole or Fulvestrantom showed doubling of the median survival rate without the disease progress compared to single hormonal therapy. This strategy called Therapy of Breakthroughs combines proven efficiency, good tolerability, maintains a high quality of life and should be used in patients with an al-positive HER2-negative metastatic breast cancer. |
| first_indexed | 2024-04-09T16:41:47Z |
| format | Article |
| id | doaj.art-e1c7a73591774fc1a650a1ae64493f76 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:41:47Z |
| publishDate | 2017-06-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-e1c7a73591774fc1a650a1ae64493f762023-04-23T06:56:40ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-06-0106303710.21518/2079-701X-2017-6-30-371861NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCERE. V. ARTAMONOVA0Blokhin Russian Oncologic Scientific Center of the Ministry of Health of RussiaThe article deals with the new oral target drug Palbociclib and its place in estrogen-receptor therapy, a positive HER2-negative metastatic breast cancer. Until recently, the consistent endocrine therapy was the primary treatment for the patients of this subgroup, as it significantly improved clinical outcomes of the disease. However, in the vast majority of cases, the tumor demonstrated the acquired, and sometimes the original, hormone resistance, which sooner or later led to failure of treatment and to the progress of the disease. Discovery of the role of cycline- dependent kinases (CDK) in the activation of the tumor proliferation and the subsequent creation of the first inhibitor, CDK 4 and 6 types of Palbociclib, led to a fundamental change in the situation: The results of the clinical examination of the combinations of Palbociclib with Letrozole or Fulvestrantom showed doubling of the median survival rate without the disease progress compared to single hormonal therapy. This strategy called Therapy of Breakthroughs combines proven efficiency, good tolerability, maintains a high quality of life and should be used in patients with an al-positive HER2-negative metastatic breast cancer.https://www.med-sovet.pro/jour/article/view/1884metastatic breast cancertherapypalbociclib |
| spellingShingle | E. V. ARTAMONOVA NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER Медицинский совет metastatic breast cancer therapy palbociclib |
| title | NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER |
| title_full | NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER |
| title_fullStr | NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER |
| title_full_unstemmed | NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER |
| title_short | NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER |
| title_sort | new strategy for drug treatment of luminal her2 negative metastatic breast cancer |
| topic | metastatic breast cancer therapy palbociclib |
| url | https://www.med-sovet.pro/jour/article/view/1884 |
| work_keys_str_mv | AT evartamonova newstrategyfordrugtreatmentofluminalher2negativemetastaticbreastcancer |